Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study

被引:135
作者
Fosbol, E. L. [1 ]
Gislason, G. H. [2 ]
Jacobsen, S. [3 ]
Folke, F. [1 ]
Hansen, M. L. [1 ]
Schramm, T. K. [1 ]
Sorensen, R. [1 ]
Rasmussen, J. N. [4 ]
Andersen, S. S. [1 ]
Abildstrom, S. Z. [1 ]
Traerup, J. [5 ]
Poulsen, H. E. [5 ]
Rasmussen, S. [4 ]
Kober, L. [2 ]
Torp-Pedersen, C. [1 ]
机构
[1] Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark
[2] Univ Copenhagen Hosp, Ctr Heart, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen Hosp, Dept Rheumatol, DK-2100 Copenhagen, Denmark
[4] Natl Inst Publ Hlth, Copenhagen, Denmark
[5] Univ Copenhagen Hosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
关键词
CARDIOVASCULAR EVENTS; CYCLO-OXYGENASE-2; INHIBITORS; HEART-FAILURE; ROFECOXIB; POPULATION; CELECOXIB; HOSPITALIZATION; CYCLOOXYGENASE; PREVENTION; IBUPROFEN;
D O I
10.1038/clpt.2008.204
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Use of some nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with increased cardiovascular risk in several patient groups, but whether this excess risk exists in apparently healthy individuals has not been clarified. Using a historical cohort design, we estimated the risk of death and myocardial infarction associated with the use of NSAIDs. Participants in the study were selected from the Danish population and were defined as healthy according to a history of no hospital admissions and no concomitant selected pharmacotherapy. The source population consisted of 4,614,807 individuals, of whom 1,028,437 were included in the study after applying selection criteria. Compared to no NSAID use, hazard ratios (95% confidence limits) for death/myocardial infarction were 1.01 (0.96-1.07) for ibuprofen, 1.63 (1.52-1.76) for diclofenac, 0.97 (0.83-1.12) for naproxen, 2.13 (1.89-2.41) for rofecoxib, and 2.01 (1.78-2.27) for celecoxib. A dose-dependent increase in cardiovascular risk was seen for selective COX-2 inhibitors and diclofenac. Caution should be exercised in NSAID use in all individuals, and particularly high doses should be avoided if possible.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 29 条
  • [1] Andersen TF, 1999, DAN MED BULL, V46, P263
  • [2] Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association
    Antman, Elliott M.
    Bennett, Joel S.
    Daugherty, Alan
    Furberg, Curt
    Roberts, Harold
    Taubert, Kathryn A.
    [J]. CIRCULATION, 2007, 115 (12) : 1634 - 1642
  • [3] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [4] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [5] The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction
    Brophy, J. M.
    Levesque, L. E.
    Zhang, B.
    [J]. HEART, 2007, 93 (02) : 189 - 194
  • [6] Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Cannon, Christopher P.
    Curtis, Sean P.
    FitzGerald, Garret A.
    Krum, Henry
    Kaur, Amarjot
    Bolognese, James A.
    Reicin, Alise S.
    Bombardier, Claire
    Weinblatt, Michael E.
    van der Heijde, Desiree
    Erdmann, Erland
    Laine, Loren
    [J]. LANCET, 2006, 368 (9549) : 1771 - 1781
  • [7] Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib
    Farkouh, M. E.
    Greenberg, J. D.
    Jeger, R. V.
    Ramanathan, K.
    Verheugt, F. W. A.
    Chesebro, J. H.
    Kirshner, H.
    Hochman, J. S.
    Lay, C. L.
    Ruland, S.
    Mellein, B.
    Matchaba, P. T.
    Fuster, V.
    Abramson, S. B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) : 764 - 770
  • [8] The pattern of use of non-steroidal anti.-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people
    Fosbol, Emil Loldrup
    Gislason, Gunnar H.
    Jacobsen, Soren
    Abildstrom, Steen Z.
    Hansen, Morten Look
    Schramm, Tina Ken
    Folke, Fredrik
    Sorensen, Rikke
    Rasmussen, Jeppe N.
    Kober, Lars
    Madsen, Mette
    Torp-Pedersen, Christian
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (08) : 822 - 833
  • [9] Gaist D, 1997, DAN MED BULL, V44, P445
  • [10] Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
    Gislason, GH
    Rasmussen, JN
    Abildstrom, SZ
    Gadsboll, N
    Buch, P
    Friberg, J
    Rasmussen, S
    Kober, L
    Stender, S
    Madsen, M
    Torp-Pedersen, C
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (10) : 1153 - 1158